Assessment of S100\u3b2 Biomarker in Acute Ischemic Cerebrovascular Stroke Patients with Hypertension

Background: Cerebrovascular stroke (CVS) is the third leading most common cause of death in the world. Role of antihypertensive drugs and nitric oxide donors such as glyceryl trinitrate (GTN) in acute ischemic cerebrovascular stroke varies in their effects on cerebral autoregulation (CA). Assessment of biochemical marker as S100\u3b2 protein is an important diagnostic tool. Objective: The aim of this study is to assess the role of transdermal glyceryl trinitrate (GTN) patch in the management of acute ischemic CVS and to evaluate the role of S100\u3b2 protein as a prognostic marker in acute ischemic CVS. Methods: Forty acute ischemic CVS patients with hypertension were included. They were divided in to two groups, Group (A); 20 patients maintained on their anti-hypertensive treatment, and Group (B); 20 patients received GTN nitro dermal patch 5mg. All cases were subjected to, clinical evaluations by European stroke scale, assessment of S100\u3b2 on third day and after 14 days of stroke onset and brain CT. Results: There was no significant statistical difference between patient groups as regard clinical stroke evaluation on third day on stroke onset but there was significant statistical difference between group (A) and (B) after 14 days of stroke. There was highly significant statistical difference in the serum level of S100\u3b2 in group (A) and (B) on third day of stroke onset. Conclusion: Using GTN nitro dermal patch is a promising solution in management of hypertension in acute ischemic CVS and S100\u3b2 may help in the prediction of its prognosis